Compare Barclays PLC (BCS) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Tenet Healthcare Corporation — how do they compare? Barclays PLC trades at $28.05 (market cap $92.56B), while Tenet Healthcare Corporation trades at $183.6 (market cap $15.82B). The key difference: Barclays PLC is far larger — about 5.9× Tenet Healthcare Corporation's market cap, and Barclays PLC pays a 1.67% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| BCS | THC | |
|---|---|---|
Market Cap | $92.56B | $15.82B |
Sector | Financials | Health |
52-Week High | $28.41 | $244.80 |
52-Week Low | $18.48 | $148.38 |
Dividend Yield | 1.67% | — |
Enterprise Value | — | $26.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.
The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.
Tenet Healthcare (THC) trades at $194.81, down 4.62% today, but maintains strong fundamentals with consistent earnings beats and attractive valuation metrics. The stock shows robust profitability with 37.87% ROE and 7.79% net margin, supported by growing outpatient care operations. Technical indicators suggest near-term bearish pressure with key support at $191 and resistance at $198. Recent analyst coverage remains overwhelmingly positive with 81% buy ratings and a $235.88 consensus target.
THC presents a compelling value opportunity with below-market P/E of 9.55 and strong earnings momentum, though technical weakness and upcoming Q2 earnings on July 24 create near-term uncertainty. The expanding ambulatory care segment and defensive healthcare positioning during geopolitical tensions support long-term growth, while debt levels and hospital industry challenges remain key monitoring points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
